ENZYMES

PRIOR AUTHORIZATION REQUEST

PRESCRIBER FAX FORM

ONLY the prescriber may complete and fax this form. This form is for prospective, concurrent, and retrospective reviews.

Incomplete forms will be returned for additional information. The following documentation is required for prior authorization consideration. For formulary information and to download additional forms, please visit https://www.bcbstx.com/provider/medicaid/star_kids_prior_auth.html

PATIENT AND INSURANCE INFORMATION				Today's Date:			
Patient Name (First):	Last:			M:	DOB (mm/dd/yy):		
Patient Address:	City, State, Zip:				Patient Telephone:		
BCBSTX ID Number:				Group Number:	•		
PRESCRIBER/CLINIC INFORMATION	ON		,				
Prescriber Name: Prescriber NPI#:				Specialty: Contact Name:			
Clinic Name:			Clinic Address:				
City, State, Zip:			Phone	Phone #:		Secure Fax #:	
PLEASE ATTACH ANY ADDITIONA	L INFOR	MATION THAT	SHOUL	D BE CONSIDERED	WITH	I THIS REQUEST	
Patient's Diagnosis-ICD code plus of	description	:					
☐ Thrombocytopenia ☐ Fabry disease ☐ Pompe disease							
☐ Severe congenital protein C deficiency ☐ Severe combined immunodeficiency disease							
☐ Hereditary tyrosinemia type I (HT-1)							
☐ Mucopolysaccharidosis I (MPS I and/or Hurler-Scheie Syndrome) ☐ Mucopolysaccharidosis II (Hunter syndrome)							
☐ Mucopolysaccharidosis VI (MPS VI, Maroteaux-Lamy syndrome)☐ Mucopolysaccharidosis IVA (Morquio A syndrome)☐ Other (ICD Code plus Description:							
						<u> </u>	
Please provide the date of diagnosi	S:					_	
Medication Requested:				Strength:			
Dosing Schedule:				Quantity per Month:			
 Is the patient currently treated with the requested medication?						Date(s): Date(s):	
adverse drug reactions).							
4. Please list all other medications the patient is currently taking for treatment of this diagnosis							
Prescriber or Authorized Signatu	re:				Dat	e:	
Prior Authorization of Benefits is not the treating physician can determine what n	practice of nedications lusions. The ted and nec	are appropriate for e submitting provid essary to the healt	r a patier ler certifi th of the	nt. Please refer to the a es that the information patient.	edical jud pplicabl		
Please fax or mail this form to:	,y. Auti				OTICE	: This communication is intended only for	
Prime Therapeutics LLC, Clinical Review Department 2900 Ames Crossing Road Eagan, Minnesota 55121			th ir	the use of the individual entity to which it is addressed and may contain information that is privileged or confidential. If the reader of this message is not the intended recipient, you are hereby notified that any			
			d	lissemination, distribu	tion or o	copying of this communication is strictly	
TOLL FREE				prohibited. If you have received this communication in error, please notify the sender immediately by telephone at 866.202.3474 and return			
Fax: 877.243.6930 Phone: 855.457.1200				the original message to Prime Therapeutics via U.S. Mail. Thank you for your cooperation.			